Delivery Nanosystem Platform
Delivery systems adapted to their features and purpose are in demand to efficiently deliver intracellular mRNA for clinical applications. An ideal delivery vehicle not only successfully transports mRNA into the desired cytoplasm, but also minimizes its specific innate immune stimulation. Based on years of experience and advanced instruments, Creative Biogene has launched a vector platform for mRNA delivery to cope with the poor stability, translational efficiency, cell targeting of synthetic mRNAs. We are committed to providing advanced delivery systems, nanosystems with greater payload capacity, involving lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs) and lipid-polymer nanoparticles (LPNs). With a focus on high encapsulation efficiency, scalability of production and low maintenance cost, our technologies are at the forefront of the mRNA-based drug research and development field.
The advantages of nanoparticles for mRNA-based drug formulation
Nanoparticles (NPs) are comprised of various biocompatible materials (e.g., polymers, lipids, and metals) with sizes around 1-100 nanometers (nm) in diameter. Thanks to the small size and intrinsic property, the NPs have been utilized to transport diverse pharmaceuticals, especially in mRNA-based drugs. By the encapsulation of mRNA within NPs, the method not only physically protects mRNA against enzymatic degradation conditions, but also allows mRNA to alter its biodistribution, cellular targeting and cellular uptake mechanism, thereby, contributing to the delivery of mRNA and mRNA-based drug outcome. Compared to viral systems, the non-viral systems have superior advantages in the case of mRNA-based products, including more safe, reproducible and economical production and among others.
Lipid nanoparticles (LNPs)
LNPs were first used for mRNA delivery in clinical studies in 2015. Based on our expertise in mRNA targeted delivery, we used combinatorial methods to identify novel compounds and optimize LNP formulations for mRNA delivery vectors. Notably, apart from high encapsulation efficiency with greater payload capacity, the LNPS provided on our platform supports a broad variety of cells or tissues.
Polymeric nanoparticles (PNPs)
PNPs hold great potential as nanocarriers for mRNA delivery owing to their easy control formulation, including the size, morphology, charge, as well as structure and so on. Based on advanced microfluidic technology that systematically optimized with the productive procedure through mediated mixing speed and ratio, we can rapidly produce homogeneous PNPs under consistent conditions. Additionally, the detailed reports of PNP properties are available according to our customers' requirements, involving the size and morphology of PNPs, the surface properties and stability as well as mRNA-PNPs interactions.
Lipid-polymer nanoparticles (LPNs)
LPNs represent the next-generation delivery systems for mRNA delivery, which integrate the physicochemical properties and advantages of both lipids and polymers. We focus on the new class of biomaterials, providing different manufacturing protocols for the assembly of LPNs, involving different composing proportions and sequential assembly routes. We believe that the potency of mRNA can achieve multiple order-of-magnitude increases when co-delivering with LPNs. We also offer physicochemical and biological characterization services and ex vivo experiments for mRNA analysis.
To improve research outcomes and the speed of success, please feel free to contact us or directly send us an inquiry.
- Sahin, U., et al. (2014). "mRNA-based therapeutics—developing a new class of drugs." Nature reviews Drug discovery, 13(10), 759-780.
- Siewert, C. D., et al. (2020). "Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA." Cells, 9(9), 2034.